At the point at which the patient’s cancer was noted to be regressing, the only treatment he was receiving for his prostate cancer was an LHRH-agonist, an agent on which he had previous documented disease progression, based on serial PSA and CT scans. Here, KLK3 is linked to prostate cancer.